Access
This article is part of Nature's premium content.
Published online 21 August 2007 | Nature | doi:10.1038/news070820-1
Column
Risky business
It's not the technology of gene therapy but the regulation of clinical trials that we should be most afraid of, says Apoorva Mandavilli.
Almost exactly seven years after the first death in a gene-therapy trial, another unexpected death hit the field late last month - followed quickly by panic, outrage and some calls for an end to gene therapy altogether.
But to blame and ban all gene therapy because of this would be rash and misguided.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
